Skip to content
Gud Knight
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Community
  • Products
  • Partnering
  • Investors
    • Overview
    • Press Releases
    • Events & Webcasts
    • Financial Reports
    • Presentations & Fact Sheets
    • Product Pipeline
    • Shareholder Information
    • Governance
    • In the News
    • E-mail Alerts
  • Careers
  • Contact Us
  • Français
Site Search

Partnering

Knight’s leadership team has an unsurpassed depth and breadth of expertise in negotiating win-win transactions to bring innovative pharmaceuticals to life. The Knight management team led by CEO Jonathan Ross Goodman has successfully worked with dozens of partners to maximize the value of their assets. Pragmatism and a strong desire to always do what is right for the business govern all our relationships.

Canada

Knight is widely considered the partner of choice for Canada. Knight’s senior leadership has a proven track record of success and has successfully collaborated with over 30 companies to structure deals designed to meet partner needs:

Commercial
• Commercialized over 60 products in Canada
• Grew Canadian revenue to ~$150M and international revenue to ~$120M
• Built sales and marketing teams/expertise across multiple therapeutic areas

Regulatory
• Significant experience in all aspects of the regulatory process
• Over 30 submissions to Health Canada with a 90% success rate

Pricing and Reimbursement
• Extensive experience and success with PMPRB, provincial formularies and private payors
• PMPRB acceptance of all major brands’ launch prices
• Track record in obtaining significant price increases in public markets
• Successfully negotiated favourable listings

We are actively seeking innovative product candidates in all therapeutic areas that will deliver novel solutions to healthcare professionals and patients across Canada.

While we are primarily interested in acquiring the rights to late-stage products, we also will license and acquire differentiated earlier-stage assets that address unmet medical needs.

International Markets

Rest of World (excluding U.S., Europe, Japan)

Knight is actively looking for potential products and companies that fit within its existing business model, but that are in select areas such as Latin America, Israel, Australia, the Middle-East, Sub-Saharan Africa, and the Caribbean. Knight is interested in acquiring an equity position in companies that are in these high growth countries which are non-core geographies. To discuss partnership opportunities, contact us at info@gudknight.com.

Knight holds a 28.3% ownership interest in Medison, Israel’s leading specialty pharmaceutical and therapeutic device company. Medison is focused on delivering innovative healthcare solutions to the Israeli market, including but not limited to early access programs, government registration and reimbursement, medical affairs, marketing, and logistics. Medison is the exclusive Israeli partner for leading global pharma companies such as Amgen®, Biogen®, Shire® and Ipsen®.

Out-Licensing

Knight is currently looking for international partners interested in-licensing the rights to the following products:

Neuragen®: Clinically proven to reduce peripheral neuropathic pain quickly and without many of the side effects common with prescription medications

Impavido: For patients with Visceral, Mucosal and Cutaneous Leishmaniasis

Strategic Lending

Knight is interested in financing life sciences companies with the goal of earning interest income, strengthening relationships in the life sciences industry and securing product distribution rights for Canada and select international markets.

Strategic Fund Investments

Knight is open to investing in life sciences venture capital funds in which we earn a return similar to any other limited partner in the fund and receive preferential access to innovative healthcare products from around the world for Canada and select international markets. To date, we have committed to invest over $125 million with 9 fund managers.

© 2019 All rights reserved | Knight Therapeutics Inc.

  • Legal Notices
  • Privacy